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Influenza vaccine: Engineered nucleoprotein with improved protective efficacy against 1 
multiple strains 2 
  3 
Circulating influenza A virus (IAV) strains differ in their surface proteins each year, and 4 
vaccines eliciting an immune response to these proteins are often only partially protective. 5 
Internal viral proteins, such as the nucleoprotein (NP), are highly conserved, and cellular 6 
immunity to NP has been correlated with protection from diverse strains. However, current 7 
IAV vaccines induce a poor immune response to NP. In this study, led by Fergal Hill from 8 
Osivax, researchers develop an oligomeric version of NP with improved immunogenicity. 9 
Vaccination of mice with oligomeric NP results in an improved NP-specific T cell response, 10 
including CD8+ tissue memory T cells in the lung, and protects mice against three different 11 
IAV subtypes. Co-administration with the currently used inactivated influenza vaccine 12 
further improves protection against virus infection in mice. These results encourage further 13 
preclinical and clinical development for this vaccine candidate. 14 
 15 
 16 
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Abstract  29 
Inactivated influenza vaccines (IIV) lack broad efficacy. Cellular immunity to a 30 
conserved internal antigen, the nucleoprotein (NP), has been correlated to protection 31 
against pandemic and seasonal influenza and thus could have the potential to broaden 32 
vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an 33 
oligomerized NP, that shows increased uptake by dendritic cells and immunogenicity 34 
compared to NP. Intramuscular immunization in mice with OVX836 induced strong 35 
NP specific CD4+ and CD8+ T cell systemic responses and established CD8+ tissue 36 
memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against 37 
viral challenge with three different influenza A subtypes, isolated several decades 38 
apart and induced a reduction in viral load. When co-administered with IIV, OVX836 39 
was even more effective in reducing lung viral load. 40 
 41 
Keywords: Influenza vaccine, recombinant Nucleoprotein, oligomerized 42 
Nucleoprotein, cellular immunity; CD8+T cells response, protection, efficacy, 43 
immunogenicity, broad-spectrum, Influenza A, pandemic, seasonal.  44 
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Introduction 45 
Inactivated influenza vaccines aim to prevent infection, and are usually partially 46 
successful. A recent meta-analysis from 2004-2015 seasons found an efficacy of 33% 47 
(confidence interval (CI) = 26%–39%) against H3N2 viruses, compared with 61% (CI 48 
= 57%–65%) against H1N1 and 54% (CI = 46%–61%) against influenza B viruses 1. 49 
During the pH1N1 pandemic of 2009, monovalent vaccines containing an adjuvant 50 
had median effectiveness of 69% (CI=60-93%) 1. But by targeting only the surface 51 
glycoproteins, current influenza vaccines run the risk of having much lower 52 
effectiveness should a mismatch occur between the strains included in the vaccine and 53 
the strains actually circulating. This happened most recently in the Northern 54 
Hemisphere during the 2014-2015 season 2, in which vaccine effectiveness was 55 
estimated to be as low as 23% 3, due to drift mutations in the hemagglutinin antigenic 56 
site B of the circulating H3 strain 4, but current influenza vaccines retain some 57 
effectiveness even when mismatches occur 5. 58 
Nonetheless, a vaccine approach based on cellular responses to conserved internal 59 
antigens could minimize the effects of antigenic drift and even mismatches. Influenza 60 
pandemics are very informative in this respect: In a retrospective serological study 6 61 
of the H2N2 pandemic of 1957, suggestive evidence was found that adults exposed to 62 
the new virus were spared from influenza more frequently than children. The author 63 
proposed that the main protective factor in adults was immunity resulting from prior 64 
infection with earlier (non-H2N2) strains. The recent H7N9 influenza outbreak, with 65 
more than 600 documented cases has been particularly instructive. Indeed, a small 66 
study of 16 hospitalized patients lacking neutralizing antibodies showed that those 67 
who recovered (12 patients) had significantly stronger CD8+, CD4+ and NK cell 68 
immune responses to the H7N9 virus than those (4 patients) who did not recover from 69 
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the infection 7. Noteworthy, early cytotoxic T lymphocyte (CTL) responses were 70 
associated with more rapid recovery 7. 71 
The H1N1 pandemic of 2009 provided further opportunities to determine whether 72 
heterosubtypic immunity to influenza exists in humans. A prospective cohort study 73 
conducted during the H1N1 pandemic of 2009 showed that individuals who 74 
developed less severe illness harbored higher frequencies of pre-existing T cells with 75 
specificity for conserved CD8 epitopes 8. In human challenge studies, on the other 76 
hand, pre-existing CD4+, but not CD8+T cells responding to influenza internal 77 
proteins were associated with lower virus shedding and less severe illness 9. 78 
 Most recently, the Flu Watch Cohort Study 10 has investigated whether pre-existing T 79 
cell responses targeting internal viral proteins could provide protective immunity 80 
against pandemic and seasonal influenza. NP is one of the most conserved internal 81 
influenza antigens; even the most divergent protein sequences differ by less than 11% 82 
11. The presence of NP-specific T cells before exposure to virus correlated with less 83 
symptomatic, PCR-positive influenza A, during both pandemic and seasonal periods, 84 
whereas other conserved antigens were at best of lesser importance 10. Additionally, it 85 
has been recently possible to demonstrate a strong immune selection against NP 86 
CD8+ epitopes in the human influenza lineage when compared to those of the swine 87 
lineage.  This observation highlights the importance of immune responses against this 88 
internal NP antigen, notably considering that other conserved viral antigens, such as 89 
the matrix (M1) protein, do not undergo a similar immune selection 12.  90 
Finally, a comprehensive study comparing systematically the conserved influenza 91 
antigens, administered in MVA, found that only vectors expressing NP, either alone 92 
or in combination with other conserved influenza proteins, protected mice against 93 
lethal challenges with H5N1, H7N1 and H9N2 13. Altogether, these studies, added to 94 
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the fact that NP contains CD8+ epitopes that can be dominant in both HLA-A2-95 
positive 14 and HLA-A2-negative humans 15, illustrate the potential utility of cellular 96 
immune responses against this conserved NP influenza antigen. NP has been regularly 97 
detected in influenza inactivated vaccine (IIV) formulations 16, 17, in variable, but 98 
sometimes considerable amounts 18. However, it has been shown that, when included 99 
in the IIV, NP exerts relatively poor CD8+ T cell immunogenicity both in humans 100 
and in mice 19. There is a need, therefore, for novel forms of influenza NP capable of 101 
significantly enhancing the immunogenicity of this antigen, even when administered 102 
with IIV. 103 
Oligomeric forms of protein antigens have been shown to be more immunogenic than 104 
the monomeric forms 20. To enhance the immunogenicity of NP, we have developed 105 
OVX313, an improved version of the oligomerization domain IMX313 21-26 created as 106 
a hybrid of the C-terminal fragments of two avian C4bp α chain sequences that 107 
naturally oligomerize into heptamers 22. The heptameric oligomerization domain 108 
OVX313 is stabilized by intermolecular disulfide bonds and the extremely high 109 
oligomer stability is an interesting scaffold for applications in the field of protein 110 
engineering and vaccines.  111 
This study describes OVX836, a recombinant protein candidate vaccine, which 112 
consists of the fusion of OVX313 with the nucleoprotein of influenza A 113 
(H1N1/WSN/1933). OVX836 increased immunogenicity over NP and protected 114 
against multiple influenza subtypes.  115 
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RESULTS 116 
Design of OVX836, based on NP fused to a small oligomerization domain and 117 
DNA based immunization  118 
We set out to make a more immunogenic version of NP by fusing it to the small 119 
oligomerization domain OVX313, derived from the previously described IMX313 21,22 120 
and described in Materials and Methods (Figure 1a). Then, to determine whether the 121 
immunogenicity of the influenza NP could be improved by fusing it to either IMX313 122 
or OVX313, four plasmids were constructed (NP, NP-IMX313, NP-OVX313= 123 
OVX836 and empty vector) and used to immunize mice. 124 
Cellular immune responses induced two weeks after the last DNA vaccination were 125 
measured in spleen by ELISpots using either NP to stimulate total T cells (Figure 1b) 126 
and purified CD4+ T cells (Figure 1c), or the immunodominant peptide NP366-374 to 127 
stimulate CD8+ T cells (Figure 1c). The administration of NP DNA alone induced a 128 
weak IFN-γ producing T cells response, not significantly different from the empty 129 
vector. On the contrary, we showed that significant amounts of NP-specific IFN-γ 130 
producing T cells, including NP-specific CD4+ and CD8+ T cells response, were 131 
induced by OVX836 DNA vaccination, the level of response being increased 132 
compared to the response achieved after empty vector, NP or NP-IMX313 DNA 133 
vaccination (p<0.01).    134 
In parallel, serum antibody responses to NP were measured 14 days after the last 135 
immunization. Mice immunized with NP alone showed only low levels of NP-specific 136 
IgG antibody responses, while OVX836 immunized mice had significantly higher IgG 137 
antibody responses compared to all other groups of immunized mice (p<0.01) (Figure 138 
1d). 139 
In summary, our results show that fusing NP to the OVX313 domain improves both 140 
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NP antigen-specific T cell and IgG antibody responses, with OVX836 showing 141 
immunogenicity superior to NP-IMX313, which is already more immunogenic than 142 
NP. 143 
OVX836 protein is an oligomeric form of NP with improved immunogenicity 144 
Based on the results obtained with DNA immunizations, two recombinant proteins 145 
were produced in Escherichia coli: NP from the prototype human isolate A/Wilson-146 
Smith/1933 (ref. 27), referred to here as NP, and the same antigen fused through its 147 
C-terminus to OVX313, called OVX836. Both OVX836 and NP proteins were 148 
purified using Heparin Sepharose affinity columns. The purity of the recombinant 149 
proteins was analyzed by SDS-PAGE under reducing and denaturing conditions 150 
(Figure 2a, left). OVX836 and NP resolved as single bands at approximatively 64 and 151 
56 kDa, as expected from the cloned amino acid sequences (theoretical MWs of 62.7 152 
and 56.2 kDa, respectively). Moreover, OVX836 and NP were recognized by a MAb 153 
raised against NP (Figure 2a, right).  154 
OVX836 and NP were then examined by means of reversed-phase (RP) 155 
chromatography, showing that purified recombinant proteins were very homogeneous 156 
(Figure 2b). Both molecules exhibited a single elution peak that represents >97% of 157 
the total protein area at 280 nm. OVX836 and NP showed a main peak corresponding 158 
to the heptameric and monomeric form of NP, respectively. As expected, treatment 159 
with the reducing agent TCEP did not modify the chromatographic profile of NP. In 160 
contrast, the reduction of disulfide bonds promoted dissociation of the OVX836 sub-161 
units into lower association states (Figure 2b), showing that intermolecular disulphide 162 
bonds were required for the stabilization of the heptameric state of OVX836 under RP 163 
conditions. Under aqueous conditions, OVX836 is heptameric independently from 164 
disulphide bonds. 165 
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Based on the results from gel filtration chromatography, the most abundant form of 166 
NP was a trimer of 150 kDa and only few monomers were observed (Supplementary 167 
Figure 1a). The analysis of the oligomeric state of purified recombinant NP has 168 
indicated a broad distribution of oligomeric states 28, 29. In contrast, a mutated version 169 
of NP did not self-associate and formed only monomers of 55 kDa as the E339A and 170 
R416A mutations in the tail loop result in the complete loss of NP trimerization 29. 171 
The heptameric state of OVX836 as well as small oligomers of heptamers (di-/tri-172 
heptamers) were consistently observed (MW in a range from 400 to 1200 kDa), that is 173 
consistent from batch-to-batch. Interestingly, the OVX836 tail loop mutant did not 174 
show small oligomers of heptamers (Supplementary Figure 1b).  175 
Therefore, OVX836 and NP are pure and homogenous proteins, and compared to the 176 
native NP trimer of 150 kDa, OVX836 is mainly organized as mono-, di- and tri-177 
heptamers under aqueous conditions (400-1200 kDa) (Supplementary Figure 1a). Our 178 
experiments also indicated that OVX836 is a stable heptamer due to noncovalent 179 
intermolecular interactions as well as the formation of disulfide bridges between the 180 
subunits. The Figure 2c shows a schematic representation of OVX836 protein 181 
heptamer. 182 
We then investigated the mechanisms by which OVX836 could be up-taken by 183 
professional antigen-presenting cells such as dendritic cells (DCs).  DCs were 184 
generated in vitro from murine bone marrow cultivated with Flt3 ligand (Flt3L), as a 185 
convenient source of pDC and cDC that are equivalent to the spleen CD8α+ and 186 
CD8α- DC 30. We first checked whether OVX836 was internalized by the different 187 
DCs subset. Imaging using ImageStreamX showed a strong internalization of 188 
OVX836, localizing in vesicles within DCs (Supplementary Figure 2a, b). Kinetic 189 
studies using flow cytometry using Alexa-647 labelled proteins (3mol dye/mol 190 
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protein) confirmed that OVX836 and NP products are rapidly internalized (within 2 191 
hours) by DC (Figure 2d). The levels of incorporation are dose and time dependent 192 
(percentage and MFI), with OVX836 being more efficiently incorporated than NP, 193 
even after 24 hours incubation. 194 
The immunogenicity of the recombinant proteins NP and OVX836 were measured in 195 
C57BL6 mice following two intramuscular (i.m) injections with doubling doses from 196 
6.25 µg to 50 µg. Fourteen days after the last immunization immune responses against 197 
the NP protein were detected by ex vivo IFN-γ ELISPOT to measure NP specific IFN-198 
γ producing T cells in response to NP stimulation (Figure 2e). The results showed that 199 
the NP induced moderate T cell immune responses and OVX836 protein was more 200 
immunogenic at all doses than NP, reaching a maximum response from 25 µg (p < 201 
0.0001). 202 
Furthermore, OVX836 elicited high titre serum NP specific IgG antibodies, which 203 
increased with the dose and were higher than with NP at all doses (p < 0.01) (Figure 204 
2f).  Together, these results demonstrated that the fusion protein OVX836 more 205 
effectively stimulates T cells and B cells than NP alone.  206 
OVX836 induces high NP specific systemic immunogenic responses, local T cells 207 
in the lung, and can be used in combination with IIV 208 
We next studied the effect of OVX836 at 25µg alone, or in association with the IIV in 209 
C57BL/6 mice, following two i.m injections; these co-administrations took place in 210 
the same hind limb but with injection into different muscles. To characterize 211 
the cellular immune responses elicited in mice, NP specific IFN-γ after the two 212 
immunizations were quantified using ELISPOT assays. In the group immunized with 213 
OVX836 or OVX836 combined with IIV, a strong NP specific IFN-γ producing T 214 
cells response was induced in the spleen and in lung. This response was significantly 215 
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higher than in control group p <0.0001 (Figure 3a-b). IIV as expected elicited only 216 
low levels of NP-specific T cell responses. In addition, in both the spleen and lung, 217 
OVX836 and the combination of OVX836 with IIV by the i.m route were highly 218 
immunogenic, inducing NP-specific CD4+ and NP366-374 -specific CD8+ T cells 219 
response more than ten-fold higher than PBS group (Figure 3c-d). 220 
To additionally characterize the NP-specific immune response induced by OVX836, 221 
we assessed the magnitude of cytokines released in the culture supernatants from the 222 
lung cells stimulated with NP366-374 peptide, using an ELISA (Mabtech). 223 
Immunization with OVX836 alone or in combination with IIV induced significantly 224 
higher levels of IFN-γ, TNF-α and IL-2 compared to control PBS or IIV group (but 225 
not IL-4) (Supplementary Figure 3) . These data suggest that OVX836 was able to 226 
induce a strong Th1 immune response in the lung with significant increases in the 227 
production of IFN-γ, TNF-α and IL-2 cytokines that can contribute to influenza 228 
clearance. 229 
Specific CD8+ T cell response in the lung and spleen by ELISpot, was induced by 230 
OVX836, suggesting that the antigen was cross presented. We also analyzed the 231 
quality of the CD8+ T cells induced by OVX836 alone or in combination with IIV. 232 
The frequency of NP366-374 -specific CD8+ T cells following immunization was 233 
assessed using pentamer staining by flow cytometry (Figure 3e, f) 14 days after the 234 
last immunization to confirm the CD8+ T cell activation. Within the spleens of mice, 235 
we observed an increased percentage of NP366-374 -specific CD8+ T cells following 236 
immunization with OVX836 alone or in combination with IIV compared to IIV or to 237 
unvaccinated groups (Figure 3e). We next analyzed the presence of NP366-374 -specific 238 
memory CD8+ T cells within the lung parenchyma using intravascular staining to 239 
exclude cells in the lung vasculature. Immunization with OVX836 induced the 240 
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generation of NP366-374 -specific memory CD8+ T cells that were located within the 241 
lung parenchyma (Figures 3f). Interestingly, the combination of OVX836 with IIV 242 
elicited even higher numbers of lung resident memory CD8+ T cells (p <0.05). These 243 
results indicate that OVX836 induced virus-specific memory CD8+ T cells that can 244 
infiltrate lung tissues.   245 
Taken together, our results demonstrate that OVX836 induces strong systemic NP-246 
specific CD4+ and CD8+ T cells responses as well as NP-specific IgG; it also induces 247 
lung memory CD8+T cells against NP localized in the lung parenchyma.  248 
Vaccination with OVX836 protects mice against lethal infection with the 249 
influenza H1N1 A/WSN/33 strain 250 
The most important feature of an effective vaccine candidate is the capacity to protect 251 
individuals against symptoms and signs of infection. To evaluate this aspect, we 252 
performed experimental infections in C57BL/6 mice previously immunized with 253 
either PBS (control), IIV, OVX836, or a combination of IIV and OVX836 254 
(OVX836/IIV), using the H1N1 A/WSN/33 influenza virus, harboring the same NP 255 
protein present in OVX836. In order to eliminate possible model-associated bias in 256 
the interpretation of results and anticipating further pre-clinical evaluation, identical 257 
experiments were also performed using the other classic influenza infection mouse 258 
model, Balb/c mice. As shown in Figure 4, intranasal (i.n.) inoculation of PBS-259 
immunized (control) mice with H1N1 A/WSN/33 influenza strain resulted in 90% 260 
mortality and 20% maximum mean weight loss in both mouse strains. On the other 261 
hand, whereas immunization with IIV conferred partial protection (60% survival 262 
rates) against the H1N1 A/WSN/33 challenge (not included in the IIV formulation) in 263 
Balb/c, it failed to protect C57BL/6 mice (10% survival rate). More importantly, both 264 
OVX836 and OVX836/IIV vaccinated groups were highly protected against viral 265 
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challenge in both mouse strains, as shown by survival rates of 90% and 100% in 266 
C57BL/6 and 100% and 100% in Balb/c mice, respectively (Figure 4a, b). 267 
Additionally, although a mild weight loss was observed in Balb/c mice immunized 268 
with OVX836 (10% maximum mean weight loss (Figure 4d), no significant weight 269 
loss (<5%) was observed for either the OVX836 or OVX836/IIV immunized in 270 
C57BL/6 (Figure 4c). OVX836 and OVX836/IIV vaccination also induced 1-log or 271 
higher reductions in lung viral titers (LVTs) compared to the PBS control group, 272 
especially in the case of the OX836/IIV combination (Figure 4e, f). Finally, both pre- 273 
and post-challenge HAI titers against the H1N1 A/WSN/33 virus as well as the viral 274 
strains contained in the IIV formulation were comparable between the two mouse 275 
strains, hence validating the IgG responses expected as a result of both IIV 276 
vaccination and challenge (Table 1). Of note, OVX836 vaccination did not induce any 277 
HAI responses, and tended to increase the HAI response toward some viral strains 278 
included in the IIV. 279 
These results demonstrate that OVX836 immunization protected both C57BL/6 and 280 
Balb/c mice against a lethal challenge infection with H1N1 A/WSN/33 strain. 281 
Moreover, when IIV and OVX836 were co-administered, decreased viral load in 282 
lungs were observed. 283 
Vaccination with OVX836 induces broad protection against lethal challenge with 284 
different influenza A subtypes. 285 
In view of the positive results obtained for H1N1 A/WSN/33 infection in two 286 
different mouse strains, we further investigated the protective capacity of OVX836 287 
against two additional influenza subtypes A, in the Balb/c lethal infection model 288 
(Figure 5). Mice were immunized with either PBS, IIV, OVX836, or a combination of 289 
IIV and OVX836 (OVX836/IIV) following the same experimental protocol described 290 
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above, and then i.n. infected with either H1N1 A/California/7/2009 (homologous to 291 
the H1N1 strain present in the IIV and containing an NP protein with 93% identity to 292 
the OVX836 NP protein) or  H3N2 A/Victoria/3/75 (heterologous to IIV and 293 
containing an NP protein with 90% identity to the OVX836 NP protein) viruses. Of 294 
note, preliminary experiments were performed in order to calibrate the viral inoculum 295 
and lung sampling time-point to obtain comparable mortality rates among the 296 
different viral strains used as well as to measure LVTs at the peak of viral replication. 297 
Infection of PBS-immunized (control) mice with H1N1 A/California/7/2009 or H3N2 298 
A/Victoria/3/75 resulted in 100% and 90% mortality, respectively, as well as >20% 299 
maximum mean weight loss in both cases (Figure 5a-b). As expected, the two IIV-300 
containing groups (IIV and OVX836/IIV) showed no signs of mortality or weight loss 301 
following infection with the H1N1 A/California/7/2009 virus, which in turn produced 302 
mild (>10%) weight loss in the OVX836 group with 100% survival rate (Figure 5a, 303 
cC). This observation is further supported by 1-log, 4-log and 6-log reductions in 304 
mean LVTs for the OVX836, IIV and OVX836/IIV groups, respectively, compared to 305 
the PBS control group (Figure 5e).  306 
IIV conferred only partial protection (40% survival and 18% weight loss) against the 307 
non-homologous H3N2 A/Victoria/3/75 virus. Conversely, both OVX836 and 308 
OVX836/IIV vaccinated groups were fully protected (100% survival) against lethal 309 
viral challenge with the H3N2 influenza A strain, yet showing 15% mean maximum 310 
weight losses. Indeed, the main difference for these two groups in terms of weight 311 
loss was driven by a shorter recovery time compared to the PBS and IIV groups 312 
(Figure 5b, d). OVX836 and OVX836/IIV vaccination induced 1-log and 2-log 313 
reductions in mean LVTs, respectively (Figure 5f). Once again, HAI titers against the 314 
viral strains used for infection as well those included in the IIV vaccine formulation 315 
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confirm the expected antibodies response following IIV vaccinations and challenge 316 
(Supplementary Table 1). Interestingly, pre-challenge H1N1 A/California/7/2009 HA 317 
titers induced by the OVX836/IIV group tended to be higher than those of the IIV 318 
group alone and OVX836 vaccination did not induce any HAI responses, consistent 319 
with the observations of Table 1. 320 
 Taken together, the results of the different challenge tests demonstrate the efficacy of 321 
OVX836 alone to provide protection against lethal viral infection with different 322 
influenza A strains. In addition, when OVX836 and IIV were combined for the 323 
vaccination, IIV being either homologous or heterologous to the viral strain used for 324 
the challenge, decrease of the viral loads in lungs were achieved.  325 
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DISCUSSION 326 
Influenza is one of the major infectious disease threats for humans in terms of annual 327 
health impact of seasonal influenza and in terms of potential dramatic global 328 
consequences of an influenza pandemic outbreak 31. Licensed influenza vaccines 329 
induce antibodies against the hemagglutinin, a highly polymorphic surface antigen, 330 
and as such, need to be reformulated and re-administered every year. A vaccine 331 
providing protective immunity against highly conserved, mostly internal, antigens 332 
could provide longer-lasting protection and cover multiple influenza subtypes 32, 33. 333 
However, even though such universal influenza vaccines are subject to much 334 
discussions and many reviews, only a handful of candidates have reached the clinical 335 
testing stage 34, 35.  Despite their limited efficacy 34, current seasonal vaccines remain 336 
the most effective way to prevent influenza outbreaks and annual vaccination is 337 
recommended for all people aged ≥6 months in the United States and Europe 36- 38. 338 
A wide consensus developed the hypothesis that NP probably plays a role in influenza 339 
protection with the induction of NP-specific CD8+ T cell responses mainly through 340 
cytotoxic T lymphocyte (CTL) cross-reactions 39 – 43, 19.  B cells activation and NP 341 
antibody response could also play a role in the protection against multiple influenza A 342 
strains 44, 19.  343 
Since the pioneering studies of Wraith and his colleagues in the 1980s, it has been 344 
shown that the influenza NP purified from virions can induce good but incomplete 345 
protection against homologous and heterologous viral challenges in mice 45. The same 346 
group had previously shown that a combination of NP and HA primed the 347 
development of cytotoxic T cells that were cross-reactive against other influenza A 348 
viruses 46.   349 
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Furthermore, several research groups reported the capacity of different NP-based 350 
vaccines to accelerate viral clearance and prevent mortality in mice subsequently 351 
challenged with either matched or mis-matched influenza A virus strains 47. In that 352 
regard, multiple studies on NP-based vaccines in the form of recombinant proteins 47-353 
51, DNA vaccines 40-42, 45-46 or viral vectors 52-56, 13, confirmed the protective role of 354 
CTL immune responses targeting NP.  355 
In this context, we developed a more immunogenic version of NP, capable of eliciting 356 
stronger and protective cytotoxic T cell responses at systemic and mucosal site (lung). 357 
We initially fused NP to our first-generation oligomerization domain IMX313 21, and 358 
then to its improved version OVX313. Comparing to the IMX313, the C-terminal part 359 
of the OVX313, includes a short arginine cationic sequence to facilitate vaccine 360 
purification through chromatography. Through a DNA-based vaccine study, we 361 
compared the level of immunogenicity generated by the “naked” NP antigen and of 362 
NP fused to our technology, and found that the fusion to IMX313 increased the 363 
immunogenicity of the NP antigen, which was further significantly boosted by fusion 364 
to OVX313. Leveraging these DNA vaccine results, we developed a recombinant 365 
protein vaccine harboring the NP protein from the prototype influenza H1N1 366 
A/WSN/33 human strain 27 fused to OVX313. Our technology platform (OVX313) 367 
enables the production of an heptamerized form of the NP antigen, an OVX836 368 
recombinant protein vaccine candidate. Several studies demonstrated that 369 
oligomerization of antigens using this platform (through OVX313 tag or its previous 370 
version IMX313) improves humoral and cellular immunogenicity in animals (Malaria 371 
antigens 23, Tuberculosis antigen 85A 24, Malaria Pfs25 antigen 25, HPV L2 antigen 372 
26). 373 
OVX836 enhanced antigen-uptake by DCs, and induced more NP-specific CD4+ and 374 
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CD8+ T cells responses as well as NP-specific IgG compared to NP alone. When we 375 
compared OVX836 alone, in combination with an inactivated influenza vaccines 376 
(IIV) and IIV alone in a mice immunization study, we showed that OVX836 377 
generated significantly higher T cell responses than IIV alone. The cellular response 378 
obtained with the combination of IIV and OVX836 was similar to the one obtained 379 
with OVX836 alone. OVX836 induced high frequencies of cross-reactive NP specific 380 
T cells, notably CD8+ T cells that were located in the lung parenchyma. For a long 381 
time, intramuscular immunization has been considered as unable to generate mucosal 382 
immune responses. In the 2016, Su, et al., have published a large review of the 383 
literature demonstrating that i.m. vaccination can promote both systemic and mucosal 384 
immune responses, and protect against mucosal pathogen challenge 57. In our study, 385 
we demonstrated that i.m. immunization with OVX836 enhances NP-specific T cell 386 
response localized in the lung parenchyma as shown by pentamer analysis using 387 
CD45 intravascular staining method.  388 
Mice challenge studies showed that OVX836 alone provides effective protection 389 
against lethal infection with different subtypes of influenza A (A/WSN/33, H1N1 or 390 
H3N2). Based on current scientific knowledge, we hypothesize that the protection 391 
provided by administration of OVX836 alone is mostly mediated by CD8+ T cell 392 
responses against the widely conserved NP antigen, with a potentiating action of 393 
CD4+ T cell responses, and the potential contribution of NP-specific antibody 394 
responses. In the 1980s, Wraith et al. made the hypothesis that immune responses 395 
against NP would not prevent infection, but rather accelerate clearance of infected 396 
cells 40, 41.  397 
This hypothesis is in line with the weight curves observed for most of the groups 398 
immunized with OVX836 alone, which experience initial body weight loss following 399 
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the viral challenge comparable to that of the PBS-vaccinated mice, but with less 400 
severity and significantly faster recovery time. As a result, it shows the potential of 401 
OVX836 to provide broad-spectrum protection against moderate to severe cases 402 
caused by multiple A-strain viruses.  Another attractive immunization strategy could 403 
be to leverage two lines of attack by associating NP-targeted CD8+ T cell response 404 
provided by OVX836 with the humoral response against HA generated by the IIV. 405 
This is supported by our results showing decrease viral loads in mice, when OVX836 406 
and IIV are used in combination, the IIV being either homologous or heterologous to 407 
the viral strain used for the challenge. Such combined vaccination strategy could 408 
prevent moderate to several cases cause by all influenza A subtypes and at the same 409 
time limit viral dissemination even when antibodies are less effective in neutralizing 410 
the virus.  411 
Furthermore, we also noticed, with some viral strains used for the HAI assay, slightly 412 
better pre-challenge HAI titers in the OVX836/IIV vaccinated groups compared to 413 
those vaccinated with IIV alone. Although the real implications of this relatively mild 414 
increase remain to be determined, a potential contribution of OVX836 to the HA-415 
specific humoral response induced by IIV might be worth further study.  416 
The broad annual vaccination recommendation for people aged >6 months with 417 
current IIV might represent a double-edged weapon in the long term, since on one 418 
side, it confers partial yet important protection against circulating strains, but on the 419 
other side, it could create a potential risk that vaccine recipients will not develop the 420 
lasting heterosubtypic immunity usually acquired through repeated natural infections 421 
38. An immunization strategy with a vaccine generating cellular response against NP, 422 
like OVX836, could present a double advantage by protecting against moderate to 423 
severe cases while not preventing subject’s natural infection and the development of 424 
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lasting heterosubtypic immunity. Based on the mice experiments conducted so far, 425 
OVX836 is a good candidate vaccine in order to effectively induce cell-mediated 426 
immunity to a conserved antigen and provide wide protection against multiple A-427 
strain influenza viruses. As NP is highly conserved with >95% homology within A-428 
strains 58, OVX836 represents an attractive standalone vaccination strategy to prevent 429 
influenza caused by circulating or emerging A-strains, especially in a case of a 430 
pandemic outbreak. In the context of limited effectiveness of licensed seasonal 431 
vaccines, OVX836 immunization strategy could also be combined with current or 432 
next generation vaccines triggering antibody responses against surface antigens in 433 
order to provide complete protection against multiple circulating and emerging A and 434 
B influenza subtypes.  435 
436 
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     METHODS 437 
OVX313, an improved version of the heptamerization domain IMX313 438 
IMX313 is a 55 amino acid protein domain, obtained as a hybrid of the C-terminal 439 
fragments of two avian C4bp proteins that naturally oligomerize into heptamers. Of 440 
note, in our IMX313 construction, avian C4bp sequences were engineered in order to 441 
minimize identities with their human counterparts. We have previously observed that 442 
following its fusion to a monomeric antigen, IMX313 allows the presentation of seven 443 
copies of the antigen to the immune system, increasing both B & T cell 444 
immunogenicity 21, 60. Based on this observation, we designed for the present study 445 
OVX313 as an optimized version of IMX313. We improved its oligomerization 446 
domain by substituting the last seven amino acids of IMX313 (originally LQGLSKE) 447 
by seven different amino acids (GRRRRRS), leaving the total length at 55 amino 448 
acids which retains a heptameric core structure stabilized by monovalent 449 
intermolecular interactions and disulfide bonds. 450 
Construction of plasmids 451 
Four plasmids were constructed for DNA immunizations by modifying pGT-h-NP, a 452 
plasmid expressing NP 59, to create four new ones. First, the human tPA signal 453 
peptide sequence was amplified and inserted in-frame with the N-terminus of the NP 454 
coding sequence in pGT-h-NP creating a eukaryotic expression plasmid (pIMX714) 455 
for secreted NP 60, using the forward primer IMX1305 (5’ 456 
CACTGAGTGACATCAAAATCATGGATGCAATGAAGAGAGGGC 3’) and the 457 
reverse primer IMX1306 (5’ 458 
CGTAAGACCGTTTGGTGCCTTGGCTAGCTCTTCTGAATCGGGCATGGATTT459 
CC 3’). This plasmid was then modified by inserting PCR products encoding either 460 
IMX313 creating the plasmid pIMX866 using the forward primer IMX1332 (5’ 461 
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CTGATGTGTGCGGAGAGG 3’) and the reverse primer IMX1039 (5’ 462 
TAGAAGGCACAGTCGAGG 3’), or OVX313 creating the plasmid pIMX867 using 463 
the forward primer IMX1293 (5’ GGTCAGGATGATCAAACGTGGG 3’) and the 464 
reverse primer IMX1039 (5’ TAGAAGGCACAGTCGAGG 3’), from plasmids in 465 
laboratory stocks. Finally, an empty vector was constructed (pIMX719), by digestion 466 
of pGT-h-NP with the enzymes XbaI and HindIII, filling-in and re-ligating the ends, 467 
thus deleting the sequence encoding tPA and NP. All plasmids were verified by DNA 468 
sequencing. Two bacterial expression plasmids were used for overproducing the 469 
nucleoprotein of the prototype human influenza isolate WS 27. A synthetic gene, 470 
codon optimized for expression in Escherichia coli and encoding OVX836, was 471 
purchased from DNA2.0 (now ATUMBIO) in the bacterial expression vector 472 
pDR441-SR. This plasmid, called pOVX836, was modified to delete the sequence 473 
encoding OVX313, creating the expression plasmid for NP (strain A/Wilson-474 
Smith/1933) called pNP. 475 
Protein production and characterization 476 
Both the NP and the OVX836 proteins were produced by using the bacterial strain 477 
BL21. Briefly, when bacterial growth reached the logarithmic phase, 0.5mM 478 
isopropyl ߚ-D-1-thiogalactopyranoside (IPTG) was used to induce expression for 16 479 
hours at 25°C. Recombinant NP and OVX836 proteins were purified by means of 480 
affinity chromatography on a Heparin-Sepharose column. The mutated form of NP 481 
(mut-NP and mut-OVX836) was an E339A/R416A mutant NP that did not self-482 
associate and formed only monomers 29, 60 (Supplementary Figure 1b). 483 
SDS-PAGE analysis 484 
Protein purity was evaluated by SDS-PAGE. Recombinant proteins were analyzed 485 
using a Criterion 4-12% Bis-tris gel (Bio-Rad), following the suppliers’ instructions. 486 
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Briefly, proteins were denatured and reduced using NuPAGE LDS sample buffer (4X, 487 
Thermo) and NuPAGE reducing agent (10X, Thermo), respectively. The samples 488 
were heated at 70°C for 10 minutes and then 0.5 µg of proteins were loaded on the 489 
Criterion 4-12% Bis-tris gel. The electrophoretic separation was carried out using a 490 
MOPS SDS running buffer at a constant voltage (200 V) for 50 minutes, using the 491 
NuPAGE antioxidant (Life Technologies). Proteins were detected using Instant Blue 492 
(Euromedex). Precision Plus Protein Standards (Bio-Rad) were used as molecular 493 
weight marker. Gel images were acquired with a Chemidoc Touch Imager (Bio-Rad) 494 
and images were then analyzed using the Image-Lab software (Bio-Rad). 495 
Western-blot 496 
Western blotting, using an antibody directed against Nucleoprotein antigen (MAb 497 
anti-NP, Clone 7B4G10G8), was performed to establish the identities of OVX836 and 498 
NP. Recombinant proteins were denatured and reduced as described previously. 1D-499 
PAGE was performed as described above. The gel was then blotted onto a 500 
nitrocellulose membrane using a Trans-blot transfer system and a Trans-blot 501 
nitrocellulose pack (Bio-Rad) following the suppliers’ instructions. Precision Plus 502 
Protein Western C Standards (Bio-Rad) were used as molecular weight markers. The 503 
membrane was blocked with 3% BSA in TBS-T (0.1%T, w/v) and then probed with 504 
the monoclonal antibody directed against NP antigen (MAb anti-NP, 1/3000). 505 
Peroxidase-conjugated goat anti-mouse secondary antibodies were purchased from 506 
Thermo (1/30000), and the chemiluminescence detection kit (Clarity ECL Western-507 
blot substrate) from Bio-Rad. Western blot signals were acquired with an instrument 508 
for western blot imaging (Chemidoc Touch Imager, Bio-Rad) and images were 509 
analyzed using the Image-Lab software (Bio-Rad). 510 
Liquid chromatography  511 
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Reversed-phase ultra-high-performance liquid chromatography (RP-UHPLC) was 512 
performed to provide information on protein homogeneity. Protein species were 513 
separated on a non-polar stationary phase with a gradient of hydrophobicity. Briefly, 514 
around 4.5 μg of protein were injected on a MAbPac RP column (Thermo, 4 μm, 2.1 515 
x 100 mm), thermostated at 40°C. The elution (0.4 mL/min) was performed using a 516 
linear gradient of acetonitrile with 0.1% TFA and monitored by UV detection at 280 517 
nm. The reducing agent TCEP (10mM final) was added to reduce proteins for RP-518 
UHPCUV analysis. 519 
High performance size exclusion chromatography (SE-UHPLC-UV) was performed 520 
in order to analyze product quaternary structures and sizes of recombinant molecules. 521 
Briefly, a BEH SEC450 (Waters, 4.6x150 mm, guard 4.6x30 mm), equilibrated at 522 
30°C, was used in combination with 50 mM Na/K2 phosphate buffer pH 6.8, 0.5M 523 
NaCl, 0.8M arginine mobile phase. Ten µg of protein sample was loaded onto the 524 
column and monitored by UV detection at 280 nm. 525 
Cell preparation and flow cytometry analysis 526 
Flow cytometry and fluorescence-based imaging flow cytometry were used to analyze 527 
the uptake of proteins labelled with Alexa Fluor 647 fluorochrome (Molecular Probes, 528 
Invitrogen Life Technologies). Bone marrow DC were generated from C57BL/6 529 
mice, cells were isolated by flushing femurs and tibias with culture medium RPMI 530 
1640 (Invitrogen) containing 10% heat-inactivated FBS, 10 μg/ml gentamicin, 2 mM 531 
l-glutamine (Invitrogen), 50 μM 2-ME (Sigma-Aldrich), and 10 mM HEPES 532 
(Invitrogen). Cells were filtrated through a 100-μm nylon cell strainer (BD Falcon), 533 
centrifuged, and cultured at 2×106 cells/ml in medium supplemented with 100 ng/ml 534 
recombinant human Flt3l (Amgen) 61. Flt3L-DC at day 7 to 8 of culture were 535 
incubated for the indicated time with Alexa647-labelled proteins. DC were washed 536 
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and incubated 15 minutes with Live Dead reagent in PBS 1X (Life technologies, 0.5 537 
µl per well). DCs were collected and stained 45 min at 4°C with antibodies specific 538 
for the murine cell surface antigens in FACS buffer (PBS1X, 1% FCS, 0.09% azide): 539 
CD11c (clone HL3), B220 (RA3-6B2), CD24 (M1/69), CD172a (P84) (all BD 540 
Biosciences). Prior to acquisition, cells were fixed in 2% paraformaldehyde. 541 
Acquisition was performed on LSR Fortessa flow cytometer (BD Biosciences) and 542 
post-collection data were analyzed using FlowJo software (TreeStar). For fluorescent 543 
imaging experiments, data and images were collected on an Amnis ImageStreamX 544 
Mark II, and at least 5000 events per sample were acquired. Data were analyzed using 545 
IDEAS software (EMD Millipore) and magnification of ×60 was used for all images 546 
shown. 547 
For in vivo experiments, intravascular staining with anti-CD45-BV421 was 548 
performed 3 min before killing of the mice, thereby staining all intravascular, but not 549 
parenchymal, lymphocytes in order to identify lung resident memory CD8+ T cells as 550 
described 62. Mouse spleens and lungs were collected and dissociated by mechanical 551 
disruption with GentleMACS Dissociator (spleens or lungs) (Miltenyi Biotec).  Single 552 
cell suspensions were stained with antibodies against CD45 (30F11), CD8a (53.6), 553 
CD44 (IM7) (all BD Biosciences), and analyzed by flow cytometry. NP-specific CD8+ 554 
T cells in lungs and spleens were detected using pentamer staining, cells were 555 
incubated with MHC class I (H-2Db) pentamers specific for influenza virus NP 366–374 556 
- PE (H2Db-ASNENMETM) (Proimmune). 557 
Animals and immunizations 558 
Six-week-old female C57BL/6 mice (Charles River Laboratories, Lyon, France) were 559 
used in all experiments, except for the challenge test, for which six-week-old female 560 
Balb/c mice (Charles River Laboratories, Quebec, Canada) were also used as 561 
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specified on each case. Animals were maintained under specific pathogen-free 562 
conditions, with ad libitum access to food and water. All animal procedures were 563 
approved by the Institutional Animal Care ethics committee of the Plateau de 564 
Biologie Expérimental de la Souris (CECCAPP_ENS_2015_004) and the Institutional 565 
Animal Care Committee of the Centre Hospitalier Universitaire de Québec (CPAC 566 
#2013-134), in full accordance with European regulations and the guidelines of the 567 
Canadian Council on Animal Care, respectively.  568 
DNA immunizations: To determine the effects of IMX313 and OVX313 on the 569 
immunogenicity of NP in plasmids, DNAs (50 µg) in endotoxin-free PBS were 570 
administered intramuscularly (i.m.) into the gastrocnemius muscle on days 0 and 14. 571 
Immunogenicity and dose-response with recombinant proteins: to compare the 572 
immunogenicity of the OVX836 protein to that of NP, mice were i.m. immunized 573 
twice three weeks apart with 6.25, 12.5, 25 or 50 µg of the respective proteins. 574 
Co-administration of OVX836 and the seasonal influenza vaccine: to determine 575 
whether the co-administration of OVX836 protein with IIV vaccines could potentially 576 
stimulate both highly specific T cell responses to nucleoprotein and increased 577 
antibody responses to hemagglutinins present in the seasonal vaccine, groups of 578 
female C57BL/6 mice were i.m. immunized twice, 21 days apart with 25 µg of 579 
OVX836, with or without IIV (Fluarix®, GSK 2014-2015 formulation, 1.5 µg of each 580 
HA in 50 µL). Immunizations were performed by injection into the gastrocnemius 581 
muscle or two different muscles (gastrocnemius and calf muscle) for double 582 
administration (OVX836 and IIV), with both injections being administered in the 583 
same hind limb.  584 
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Blood samples were collected before each immunization and two weeks or (14 days) 585 
after the booster immunization, mice were sacrificed and both serum, lung and 586 
splenocytes were collected from each mouse and processed individually.  587 
Mice Challenge studies 588 
Influenza challenge studies were conducted at the Infectious Disease Research Centre 589 
of the CHU de Quebec and Laval University (Quebec, Canada) and at the Plateau de 590 
Biologie Expérimental de la Souris (Lyon, France). Groups of 12 female C57BL/6 or 591 
Balb/c mice were immunized in two different muscles of the same hind limb with 592 
either 25 µg (in 25 µl) of the OVX836 protein, of the IIV (Fluviral®, GSK 2014-2015 593 
or Influvac®, 1.5 µg of each HA in 50 µL), or a combination of both (OVX836/IIV). 594 
Two immunizations (21 days apart) were performed for each group, and a PBS-595 
immunized group was included as control. Three weeks after the second 596 
immunization, mice were again lightly anesthetized by isoflurane and infected 597 
through an intranasal instillation with 20 µl of a viral suspension, containing either 598 
3LD50 of influenza H1N1 A/California/7/2009, 1LD50 (in Balb/c mice) or 2LD50 (in 599 
C57BL/6 mice) of H1N1 A/WSN/33 or 1LD50 of H3N2 A/Victoria/5/72 strain, as 600 
indicated in each case. Of note, the H1N1 A/California/7/2009 strain is homologous 601 
to the H1N1 strain present in the IIV vaccine, while the other two strains used in this 602 
study are not. All mice were monitored daily for survival and weight loss during 14 603 
days. Four mice per group were randomly chosen and sacrificed on day 4 604 
(A/California/7/2009 and A/WSN/33) or 5 (A/Victoria/5/72) post-challenge, and their 605 
lungs were aseptically removed for the determination of lung viral titers (LVTs) by 606 
standard plaque assay in MDCK cells. Serum samples were collected from each 607 
animal before each immunization and viral challenge, as well as on day 21 post-608 
challenge, to evaluate the specific IgG antibody response by Hemagglutination 609 
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Inhibition (HAI) assays. Serologic tests were performed against the same virus strains 610 
used for the viral challenge as well as the strains contained in the IIV vaccine 611 
(A/California/7/2009 (H1N1), A/Texas/50/2012 and B/Massachusetts/2/2012), 612 
following the standard WHO guidelines 63. 613 
Ex-vivo IFNγ Enzyme-Linked ImmunoSpot (ELISpot) Assay 614 
Influenza NP-specific T cells secreting IFN-γ were enumerated using an IFN-γ 615 
ELISPOT assay (Mabtech). Lymphocytes were isolated from the spleen and the lung 616 
from individual mice. CD4+ T cells were purified by positive selection using a 617 
MACS Isolation Kit for mice with CD4 (L3T4). ELISpot plates were coated with the 618 
capture mAb (#3321-2H) then incubated overnight at 4°C according to the 619 
instruction manual of Mabtech. Then 2×105 T cells and CD4+ cells were cultured for 620 
20 hours at 37°C/5% CO2 with 5 µg/mL of recombinant NP protein (OSIVAX). In 621 
addition, 2×105  T cells  were stimulated in similar conditions with 5 µg/mL of the 622 
NP366-374 (GenScript) immunodominant peptide epitope in C57BL/6 mice presented 623 
by H-2Db  to stimulate CD8+ T cells 64. Concavalin A (Sigma) was used as a positive 624 
control and unstimulated splenocytes/lung cells were used as negative controls.  Spots 625 
were counted with an ELISPOT reader system (CTL-ImmunoSpot® S6 Ultra-V). The 626 
number of protein-or peptide reactive cells was represented as spot forming cells 627 
(SFCs) per 2×105  cells per well.  628 
Cytokine production by ELISA after in vitro stimulation  629 
For analysis of cytokine secretion, lung cells were cultured (2 × 106 cells/ml) for 48h 630 
with 5µg/ml peptide NP366-374. Supernatants were collected and cytokine production 631 
was measured by sandwich ELISA kit (Mabtech) for IFNƔ (3511-1H), IL-2 (3311-632 
1H), TNFα (3441-1H), and IL-4 (3321-1H) according to the protocols provided by the 633 
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manufacturer. Cytokine concentrations in pg/ml were quantified using an appropriate 634 
standard curve.  635 
Antibody Enzyme Linked Immunosorbent Assay (ELISA) 636 
Levels of Immunoglobulin G (IgG) were measured in serum samples collected on 637 
days 35. The 96-well ELISA plates were pre-coated with 100 µL of recombinant NP 638 
(OSIVAX) at 5 µg/mL overnight at 4 °C. A total of 100 µl of serial 2-fold dilutions of 639 
sera from each group of immunized mice were added to each well and incubated for 2 640 
h at 25 °C. Bound antibody was detected with goat anti-mouse IgG-HRP (Life 641 
Technology) and finally, 100 μl of tetramethylbenzidine (TMB) (Interchim) substrate 642 
was added to each well. The antibody levels in serum were expressed as logarithm of 643 
endpoint dilution titer and this is defined as the reciprocal of the highest analytic 644 
dilution that gives a reading 3-fold over the mean O.D. 650 value of the negative-645 
control mice serum at the 1/100 dilution. A value of 1.70 (log) was arbitrarily chosen 646 
to illustrate a titer <100. 647 
Statistical Analysis 648 
Statistical analysis. The plotting of data and statistical analysis were performed using 649 
GraphPad Prism 7 software. Statistical significance was determined using the 650 
unpaired, one-way analysis of variance (ANOVA) with Tukey’s multiple 651 
comparisons test or non-parametric Kruskal-Wallis test followed by Dunn’s multiple 652 
comparisons test. Differences were considered significant if the p value was p<0.05. 653 
Survival rates of mice were compared using Kaplan Meier survival analysis, and 654 
statistical significance was assessed using the Log-Rank (Mantel-Cox) test. For 655 
weight loss curves, groups were compared at each day post-infection using Kruskal-656 
Wallis test followed by Dunn’s multiple comparison test.  657 
  658 
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The data that support the findings of this study are available from the corresponding 660 
author upon reasonable request.  661 
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Figure Legends  878 
Figure 1.  DNA based immunization with NP fused to a small oligomerization 879 
domain 880 
(a) Primary structure of OVX313 oligomerization domain and alignment with 881 
IMX313 and the homologous human C4BP-alpha. Residues in bold type are identical. 882 
Cysteine residues are highlighted in yellow. (b) C57BL/6 mice were immunized with 883 
DNA plasmid encoding NP, NP-IMX313, OVX836 (NP-OVX313), or the empty 884 
vector by the intramuscular route. NP-specific IFN-γ secreting cells were evaluated 885 
by ELISpot in splenic cells. The results represent the mean (line) and individual data 886 
points of each of the five mice with standard deviation of the mean (SD). (c) IFN-γ 887 
secreting CD4+ and CD8+ T cell, in the splenocytes stimulated with 5µg/ml of NP 888 
protein or 5µg/ml of NP366-374, respectively. (d) Serum anti-NP IgG were determined 889 
using ELISA. Sera were individually tested in serial dilutions against purified NP 890 
protein. The mean (line) of each group is represented with SD. Levels of IgG are 891 
expressed as Log (endpoint dilution titer). Differences were assessed by 1-way 892 
ANOVA followed by Tukey's multiple comparison test with 95% confidence interval, 893 
p<0.05 is considered significant. The asterisks refer to the level of significance 894 
(*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001). Results from a representative 895 
experiment of two performed is shown. 896 
  897 
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Figure 2. OVX836 protein is an oligomeric form of NP with improved 898 
immunogenicity 899 
(a) Representative SDS-PAGE analysis of OVX836 and NP proteins. Polypeptides 900 
were fractionated on 4-12 % Bis-tris gels and stained with Instant Blue, total protein 901 
were stained (left panel) or blotted onto a membrane and probed with anti-NP Mab 902 
(right panel). OVX836 and NP migrated at 64 and 56 kDa, respectively (lanes 1 and 903 
2). Molecular weight (MW) markers (lanes M). The SDS-PAGE and the Western-blot 904 
derive from the same experiment and were processed in the same day. (b) 905 
Recombinant protein species were separated by reversed-phase (RP) liquid 906 
chromatography: The Rt of ∼5.45 min (red chromatogram) corresponds to the 907 
oligomeric structure of OVX836, and the Rt of ∼5.22 min to the monomer of NP. 908 
Noncovalently bonded sub-units, most likely dimers, trimers and tetramers of NP, 909 
were chromatographically separated from oligomeric OVX836 following reduction 910 
(red dashed line). Intensity (Int). (c) Schematic representation of OVX836 protein 911 
heptamer. (d) Kinetics of incorporation of OVX836-Alexa647 by Flt3L-DC Bone 912 
marrow. DC were incubated for 2, 6 or 24 hours with OVX836-Alexa647 or NP-913 
Alexa647 (50µg/ml) at 37°C and surface stained for CD11c and B220. Alexa647 MFI 914 
of cDC (CD11c+, B220-) and pDC (CD11c+, B220+) populations were measured. 915 
Data show means ± S.D. of two independent experiments. (e) Comparison of NP-916 
specific IFN-γ producing cells evaluated by ELISpot in total splenic cells (C57BL/6 917 
mice immunized twice, intramuscularly, with 6.25, 12.5, 25 and 50µg of NP or 918 
OVX836). Results show number of IFN-γ secreting cells per 2×105 cells per well. (f) 919 
NP-specific IgG were measured by ELISA in serum from the same C57BL/6 mice 920 
groups. Levels of IgG are expressed as Log (endpoint dilution titer). The results 921 
represent the mean (line) and individual data points of each of the five mice with SD. 922 
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Differences were assessed by 1-way ANOVA followed by Tukey's Multiple 923 
comparison test with 95% confidence intervals; p<0.05 is considered significant 924 
(****p<0.0001) or by two-way ANOVA followed by a Dunnett’s multiple 925 
comparison test (multiple time points) (**p <0.01; ****p< 0.0001). These 926 
experiments were performed 3 times with similar results.   927 
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Figure 3. OVX836 vaccine alone or combined with inactivated seasonal 928 
influenza vaccine induced humoral and cellular responses in the periphery 929 
and in the lung 930 
 C57BL/6 mice were immunized twice, intramuscularly with 25µg of OVX836; with 931 
50µL of IIV (1.5µg of each HA); or with both combined (OVX836/IIV), by injection 932 
into two different muscles in the same hind limb. A group injected with PBS was used 933 
as control. (a, b) cellular immunogencity following immunization in mice. NP-934 
specific IFN-γ secreting T cells (Spot forming cells SFC) evaluated by ELISPOT per 935 
2×105 cells in the spleen and in the lung compartments. Results are shown for 3 936 
independent experiments. The results represent the mean (line) and individual data 937 
points of each of the five mice. (c, d) Comparison of specific IFN-γ secreting CD4+ 938 
and CD8+T-cell evaluated by ELISPOT in the spleen or in the lung compartments. (e, 939 
f) NP-specific CD8+T cells in the spleen and lung compartments were detected by 940 
flow cytometry using pentamer staining (H2Db-ASNENMETM). (e) Number of 941 
Pentamer CD8+T cells in the spleen and (f) in the lung. Lung parenchyma (resident) 942 
cells were identified using anti-CD45 intra-vascular staining. Data are representative 943 
of three independent experiments (mean of five mice per group). Differences were 944 
assessing by 1-way ANOVA followed by Tukey's Multiple comparison test with 95% 945 
confidence intervals; p<0.05 is considered significant (*p<0.05, **p<0.01, 946 
****p<0.0001).  947 
  948 
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Figure 4. Vaccination with OVX836 protects mice against lethal infection with 949 
influenza H1N1 A/WSN/33 strain 950 
Groups of 12 female C57BL/6 (a, c, e) or Balb/c mice (b, d e) received two 21-days-951 
appart i.m. immunizations with either PBS, IIV, OVX836, or a combination of IIV 952 
and OVX836 (OVX836/IIV). Three weeks after the second immunization, mice were 953 
i.n. infected with 2LD50 (C57BL/6) or 1LD50 (Balb/c) of H1N1 A/WSN/33 virus. (a-954 
b) Percent survival rates. *p<0.05, **p<0.01 and ***p<0.001 by Log-Rank (Mantel-955 
Cox) or Kruskal-Wallis (Dunn’s multiple comparison) tests. (c-d) mean weight 956 
changes (±SEM), (e-f) mean lung viral titers expressed as log (PFU/mL ±SD) on day 957 
4 post infection. Individual virus titers are given and lines represent averages. 1.7 log 958 
PFU/mL is the detection limit of the technique (dotted line). Statistical significance of 959 
the variance between multiple groups was calculated with Kruskal-Wallis test 960 
followed by Dunn’s multiple comparison test (* p<0.05, *** p <0.001, **** p 961 
<0.0001).  962 
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Figure 5. Vaccination with OVX836 induces broad protection against lethal 963 
challenge with different influenza A subtypes  964 
Groups of 12 female Balb/c mice received two 21-days-appart i.m. immunizations 965 
with either PBS, inactivated influenza vaccine (IIV), OVX836, or a combination of 966 
IIV and OVX836 (OVX836/IIV). Three weeks after the second immunization, mice 967 
were i.n. infected with either 3LD50 of influenza H1N1 A/California/7/2009 (left 968 
panel) or 1LD50 of H3N2 A/Victoria/5/72 (right panel) virus. (a, b) Percent survival 969 
rates. *p<0.05, **p<0.01 and ***p<0.001 by Log-Rank (Mantel-Cox) (c-d) mean 970 
weight changes (±SEM), (e, f) mean lung viral titers expressed as log (PFU/mL ±SD) 971 
on day 4 or 5 post infection. Individual virus titers are given and lines represent 972 
averages. 1.7 log PFU/mL is the detection limit of the technique (dotted line). 973 
Statistical significance of the variance between multiple groups was calculated with 974 
Kruskal-Wallis test followed by Dunn’s multiple comparison test (*p<0.05, ***p 975 
<0.001 ,****p <0.0001).  976 
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Table 1. Hemagglutination Inhibition (HAI) titers. Serologic tests against the 977 
virus strain used for the viral challenge as well as the strains contained in the IIV 978 
vaccine 979 
HAI titers were measured in pooled serum samples (3 pools per group) and expressed 980 
as the reciprocal of the limit dilution. Serologic tests were performed against the same 981 
virus strain used for the viral challenge (H1N1 A/WSN/33 virus), as well as the 982 
strains contained in the IIV vaccine (A/California/7/2009 (H1N1), A/Texas/50/2012 983 
and B/Massachusetts/2/2012).  984 
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c d
                  10        20        30        40        50        60 
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c d
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Table 1 Hemagglutination Inhibition (HAI) titers. Serologic tests against the virus strain used for the 
viral challenge as well as the strains contained in the IIV vaccine  
 
 
* Strain used for viral challenge    
** Results from one remaining mouse 
 
Viral strain used for HAI assay
A/WSN/33
 A/California/2009 A/Texas/54 B/Massachusetts 
Pre Post Pre Post Pre Post Pre Post
Challenge Challenge Challenge Challenge 
C5
7B
L/
6 
m
ic
e 
PBS 
Pool 1 <10 
80**
<10
<10**
<10
<10**
<10 
<10**Pool 2 <10 <10 <10 <10 
Pool 3 <10 <10 <10 <10 
OVX836 
Pool 1 <10 320 <10 <10 <10 <10 <10 <10
Pool 2 <10 320 <10 <10 <10 <10 <10 <10
Pool 3 <10 320 <10 <10 10 <10 <10 <10
IIV 
Pool 1 <10 
160**
20
20** 
80
40** 
10 
10** Pool 2 <10 20 40 10 
Pool 3 <10 10 80 <10 
OVX836 
/IIV 
Pool 1 20 160 80 80 40 20 20 10
Pool 2 <10 160 40 40 40 40 20 20
Pool 3 20 160 80 80 40 20 20 10
Ba
lb
/c
 m
ic
e 
PBS 
Pool 1 <10 
160**
<10
<10**
<10
<10**
<10 
<10**Pool 2 <10 <10 <10 <10 
Pool 3 <10 <10 <10 <10 
OVX836 
Pool 1 <10 160 <10 <10 <10 <10 <10 <10
Pool 2 <10 80 <10 <10 <10 <10 <10 <10
Pool 3 <10 160 <10 <10 <10 <10 <10 <10
IIV 
Pool 1 <10 160 20 80 160 320 10 20
Pool 2 <10 160 20 80 160 160 10 10
Pool 3 <10 80 10 40 80 80 10 10
OVX836 
/IIV 
Pool 1 <10 80 40 40 40 40 20 10
Pool 2 <10 160 40 40 80 80 10 10
Pool 3 10 160 40 40 160 320 10 20
